Literature DB >> 21445560

Treatment of ventricular tachycardia in patients with heart failure.

Michael W Fong1, Luanda Grazette, David Cesario, Michael Cao, Leslie Saxon.   

Abstract

Heart failure is a major public health concern that is frequently complicated by ventricular arrhythmias. Sustained ventricular tachycardia is associated with an increased risk for progressive heart failure and sudden death. We summarize the current management strategies for ventricular tachycardia in heart failure patients, including implantable cardioverter-defibrillator therapy, pharmacologic therapy, catheter ablation techniques, ventricular assist device therapy, and heart transplantation.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21445560     DOI： 10.1007/s11886-011-0182-5

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN： 1523-3782            Impact factor:   2.931


  45 in total

Review 1.  Antiarrhythmic and nonantiarrhythmic drugs for sudden cardiac death prevention.

Authors:  Mithilesh K Das; Douglas P Zipes
Journal:  J Cardiovasc Pharmacol       Date:  2010-05       Impact factor: 3.105

2.  Indications for implantable cardioverter-defibrillators based on evidence and judgment.

Authors:  Robert J Myerburg; Vivek Reddy; Agustin Castellanos
Journal:  J Am Coll Cardiol       Date:  2009-08-25       Impact factor: 24.094

3.  Improved survival among ventricular assist device recipients with a concomitant implantable cardioverter-defibrillator.

Authors:  Daniel J Cantillon; Khaldoun G Tarakji; Dharam J Kumbhani; Nicholas G Smedira; Randall C Starling; Bruce L Wilkoff
Journal:  Heart Rhythm       Date:  2010-01-04       Impact factor: 6.343

4.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

5.  Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator.

Authors:  Paul Dorian; Martin Borggrefe; Hussein R Al-Khalidi; Stefan H Hohnloser; Jose M Brum; Daljit S Tatla; Johannes Brachmann; Robert J Myerburg; David S Cannom; Michael van der Laan; Michael J Holroyde; Igor Singer; Craig M Pratt
Journal:  Circulation       Date:  2004-11-08       Impact factor: 29.690

6.  Successful radiofrequency ablation therapy for intractable ventricular tachycardia with a ventricular assist device.

Authors:  Satoru Osaki; Cesar Alberte; Margaret A Murray; Rinjal D Brahmbhatt; Maryl R Johnson; Niloo M Edwards; Takushi Kohmoto
Journal:  J Heart Lung Transplant       Date:  2008-03       Impact factor: 10.247

7.  Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA)

Authors:  H C Doval; D R Nul; H O Grancelli; S V Perrone; G R Bortman; R Curiel
Journal:  Lancet       Date:  1994-08-20       Impact factor: 79.321

8.  Successful biventricular circulatory support as a bridge to cardiac transplantation during prolonged ventricular fibrillation and asystole.

Authors:  D J Farrar; J D Hill; L A Gray; T A Galbraith; E Chow; J J Hershon
Journal:  Circulation       Date:  1989-11       Impact factor: 29.690

Review 9.  Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials.

Authors:  Jonathan P Piccini; Jeffrey S Berger; Christopher M O'Connor
Journal:  Eur Heart J       Date:  2009-03-31       Impact factor: 29.983

10.  Use of the Impella microaxial blood pump for ablation of hemodynamically unstable ventricular tachycardia.

Authors:  Hussam Abuissa; John Roshan; Bernard Lim; Samuel J Asirvatham
Journal:  J Cardiovasc Electrophysiol       Date:  2009-12-21
View more
  1 in total

1.  Overexpression of Sema3a in myocardial infarction border zone decreases vulnerability of ventricular tachycardia post-myocardial infarction in rats.

Authors:  Ren-Hua Chen; Yi-Gang Li; Kun-Li Jiao; Peng-Pai Zhang; Yu Sun; Li-Ping Zhang; Xiang-Fei Fong; Wei Li; Yi Yu
Journal:  J Cell Mol Med       Date:  2013-05       Impact factor: 5.310
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.